Literature DB >> 30507616

Papillary Renal Cell Carcinoma (PRCC): An Update.

Mohammed Akhtar1, Issam A Al-Bozom1, Turki Al Hussain2.   

Abstract

Papillary renal cell carcinoma (PRCC) is the second most common type of renal carcinoma following clear cell renal cell carcinoma. Papillary renal cell carcinoma is usually divided histologically into 2 types namely, type 1 and type 2. This classification, however, is unsatisfactory as many of papillary carcinoma are unclassifiable by the existing criteria. In recent years there has been a remarkable progress in our understanding of the molecular basis of PRCC. These studies have revealed that type 2 PRCCs represent a heterogenous group which may be subdivided into additional subtypes based on the genetic and molecular make up of these tumors and reflecting different clinical course and prognosis. Some of the molecular features such a hypermethylation of CPG islands in the promotor regions of genes and over expression of the antioxidant pathways within tumor cells have been recognized as markers of poor prognosis. Targeted therapies for papillary carcinoma in the past have been unsuccessful because of lack of clear understanding of the molecular basis of these tumors. It is hoped that recent progress in our understanding of the pathogenesis of various subtypes of PRCC, effective targeted therapies will eventually emerge in due course.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30507616     DOI: 10.1097/PAP.0000000000000220

Source DB:  PubMed          Journal:  Adv Anat Pathol        ISSN: 1072-4109            Impact factor:   3.875


  35 in total

1.  LPAR2-mediated action promotes human renal cell carcinoma via MAPK/NF-κB signaling to regulate cytokine network.

Authors:  Yuewu Wang; Zhimin Qi; Ze Li; Shuyu Bai; Alatangaole Damirin
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-20       Impact factor: 4.322

2.  [Clinicopathological features and prognostic analysis of papillary renal cell carcinoma].

Authors:  E S Bo; P Hong; Y Zhang; S H Deng; L Y Ge; M Lu; N Li; L L Ma; S D Zhang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-08-18

3.  Functional magnetic resonance imaging for distinguishing type of papillary renal cell carcinoma: a preliminary study.

Authors:  Qingqiang Zhu; Jing Ye; Wenrong Zhu; Jingtao Wu; Wenxin Chen; Jun Ling
Journal:  Br J Radiol       Date:  2021-09-07       Impact factor: 3.629

4.  Comparative study of CT and MRI appearances in mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma.

Authors:  Dajun Lu; Weibiao Yuan; Qingqiang Zhu; Jing Ye; Wenrong Zhu; Wenxin Chen
Journal:  Br J Radiol       Date:  2021-09-03       Impact factor: 3.629

5.  Giant Polycystic Papillary Renal Cell Carcinoma: A Case Report and Literature Review.

Authors:  Zhongming Huang; Hai Wang; Zhigang Ji
Journal:  Front Oncol       Date:  2022-05-12       Impact factor: 5.738

6.  The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets.

Authors:  Jin-Shu Pang; Zhe-Kun Li; Peng Lin; Xiao-Dong Wang; Gang Chen; Hai-Biao Yan; Sheng-Hua Li
Journal:  Oncol Rep       Date:  2019-02-14       Impact factor: 3.906

7.  Bioinformatics analysis of molecular genetic targets and key pathways for hepatocellular carcinoma.

Authors:  Junxue Tu; Jingjing Chen; Meimei He; Hongfei Tong; Haibin Liu; Bin Zhou; Yi Liao; Zhaohong Wang
Journal:  Onco Targets Ther       Date:  2019-07-02       Impact factor: 4.147

8.  Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial.

Authors:  Toni K Choueiri; Daniel Y C Heng; Jae Lyun Lee; Mathilde Cancel; Remy B Verheijen; Anders Mellemgaard; Lone H Ottesen; Melanie M Frigault; Anne L'Hernault; Zsolt Szijgyarto; Sabina Signoretti; Laurence Albiges
Journal:  JAMA Oncol       Date:  2020-08-01       Impact factor: 31.777

9.  Comparison of clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma.

Authors:  Xiang Le; Xiang-Bo Wang; Hao Zhao; Ren-Fu Chen; Peng Ge
Journal:  BMC Urol       Date:  2020-09-15       Impact factor: 2.264

10.  Prognostic risk signature based on the expression of three m6A RNA methylation regulatory genes in kidney renal papillary cell carcinoma.

Authors:  Zhuolun Sun; Changying Jing; Chutian Xiao; Tengcheng Li; Yu Wang
Journal:  Aging (Albany NY)       Date:  2020-11-07       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.